Unveiling an ALS Blood Transcriptomic Signature: A Machine Learning Classifier Distinct from Neurodegenerative Controls
Source check: Source checked. Not independent scientific confirmation.
Finding: The paper reports distinct cross-disease transcriptomic profiles and a linear ALS signature, with AUC 0.74 under external validation; nonlinear models overfit in validation.
Technology: LASSO logistic regression selects/regularizes genes from transcriptomic comparisons; tenfold stratified CV tunes predictive models, with SVM and Random Forest used as nonlinear comparators.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- LASSO logistic regression selects/regularizes genes from transcriptomic comparisons; tenfold stratified CV tunes predictive models, with SVM and Random Forest used as nonlinear comparators.
- Test and result
- The paper reports distinct cross-disease transcriptomic profiles and a linear ALS signature, with AUC 0.74 under external validation; nonlinear models overfit in validation. Discovery and independent GEO cohorts were analyzed; ALS external validation includes GSE112680 (164 cases, 137 controls). The evidence is retrospective/public-data classification, not prospective clinical diagnostic validation; cohort/platform heterogeneity and non-ALS model instability limit interpretation.
- Limitation / still unknown
- not a clinically validated diagnostic test.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://link.springer.com/article/10.1007/s12021-026-09780-7
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.